机构：[1]Department of Rheumatology and Immunology, the First Affiliated Hospital of Harbin Medical University, Harbin, China[2]Department of Rheumatology and Immunology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China[3]Department of Rheumatism, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China[4]Department of Rheumatology, Beijing Chaoyang Hospital Affiliated to Capital University of Medical Sciences, Beijing, China北京朝阳医院[5]Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院[6]Department of Rheumatology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China[7]University of Tasmania, Tasmania, Australia[8]Department of Radiology, Beijing Hospital, National Center of Gerontology, Beijing, China[9]Department of Rehabilitaion Medicine, Beijing Hospital, National Center of Gerontology, Beijing, China[10]Department of Orthopaedics, Peking University People’s Hospital, Beijing, China[11]Department of Rheumatology, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China[12]Shenzhen Futian Hospital for Rheumatic Diseases, Shenzhen, China[13]Department of Rheumatology and Immunology, the People’s Hospital of the Xinjiang Uygur Autonomous Region, Urumqi, China[14]Department of Rheumatology and Immunology, the First Affiliated Hospital of Anhui Medical University, Hefei, China[15]Department of Rheumatic Immunology, the First Affiliated Hospital of China Medical University, Shenyang, China[16]Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China[17]Department of Rheumatology, Second Xiangya Hospital, Central South University, Changsha, China[18]Department of Rheumatology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China浙江大学医学院附属第一医院[19]Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China[20]Department of Paediatrics and Adolescent Medicine, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China[21]Department of Orthopedics, Beijing Jishuitan Hospital, Beijing, China[22]Department of Sports Medicine and Adult Reconstructive Surgery, Drum Tower Hospital, School of Medicine, Nanjing University, Nanjing, China[23]Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University and VA Portland Health Care System, Portland, OR, USA[24]Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, WHO Collaborating Centre for Guideline Implementation and Knowledge Translation, Lanzhou, China[25]Academic Rheumatology, Clinical Sciences Building, University of Nottingham, City Hospital, Nottingham, UK[26]Department of Internal Medicine, Kaohsiung Medical College, Kaohsiung[27]Department of Orthopedic, Xiangya Hospital, Central South University, Changsha, China[28]Department of Arthrology, Guanghua Integrative Medicine Hospital, Shanghai, China[29]Department of Rheumatology and Immunology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China[30]Department of Rheumatology and Immunology, Southwest Hospital, Army Medical University, Chongqing, China[31]Guangdong Provincial Hospital of Chinese Medicine, Guangdong Provincial Academy of Chinese Medical Sciences, The Second Clinical School of Guangzhou University of Chinese Medicine, Guangzhou, China广东省中医院[32]Department of Orthopedics, Peking University People’s Hospital, Beijing, China[33]Division of Allergy, Immunology and Rheumatology, Department of Medicine, Chung Shan Medical University Hospital, Taichung[34]Veterans General Hospital, Taipei and National Yang-Ming Medical University, Taipei
Osteoarthritis (OA) is a degenerative disease of middle-aged and elderly people, contributed a higher burden of disease in China and the world. In 2017, under the support of the Rheumatology and Immunology Expert Committee of the Cross-Strait Medical and Health Exchange Association. The objective was to develop an evidence-based diagnosis and treatment guideline for OA in China based on emerging new evidence. The guideline was registered at International Practice Guidelines Registry Platform (IPGRP-2018CN028). The grading of recommendations assessment, development and evaluation (GRADE) approach was used to rate the quality of evidence and the strength of recommendations, and the RIGHT (Reporting Items for Practice Guidelines in Healthcare) checklist was followed to report the guideline. The guideline provides recommendations for the OA diagnosis, disease risks monitoring and evaluate, treatment purpose and physical, medical and surgical interventions. This guideline is intended to serve as a tool for Chinese clinicians for the best decisions-making on diagnosis and treatment of OA.
基金：
This guideline was supported by: (I) China National Centre for Biotechnology Development, Ministry of Science and Technology of China (No. 2019YFC1709805); (II) National Key R&D Program of China (No. 2018YFC1705503).
第一作者机构：[1]Department of Rheumatology and Immunology, the First Affiliated Hospital of Harbin Medical University, Harbin, China
共同第一作者：
通讯机构：[*1]Department of Rheumatology and Immunology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China[*2]Department of Orthopedics, Peking University People’s Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing, China[*3]Division of Allergy, Immunology and Rheumatology, Department of Medicine, Chung Shan Medical University Hospital, No. 110, Sec.1, Jianguo N. Rd., 40201, Taichung.[*4]Veterans General Hospital, Taipei and National Yang-Ming Medical University, No. 201, Sec. 2, Shipai Rd., Beitou District, 11217, Taipei.[*5]Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, No. 41 Damucang Hutong, Xicheng District, Beijing, China
推荐引用方式(GB/T 7714)：
Zhiyi Zhang,Cibo Huang,Quan Jiang,et al.Guidelines for the diagnosis and treatment of osteoarthritis in China (2019 edition)[J].ANNALS OF TRANSLATIONAL MEDICINE.2020,8(19):1213.doi:10.21037/atm-20-4665.
APA：
Zhiyi Zhang,Cibo Huang,Quan Jiang,Yi Zheng,Yi Liu...&Xiaofeng Zeng.(2020).Guidelines for the diagnosis and treatment of osteoarthritis in China (2019 edition).ANNALS OF TRANSLATIONAL MEDICINE,8,(19)
MLA：
Zhiyi Zhang,et al."Guidelines for the diagnosis and treatment of osteoarthritis in China (2019 edition)".ANNALS OF TRANSLATIONAL MEDICINE 8..19(2020):1213
